Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.70 Bil Enterprise Value: 10.12 Bil PE Ratio: 113.19 PB Ratio: 2.90 GF Score: 82/100

Qiagen NV at UBS Global Healthcare Conference Transcript

May 24, 2022 / 02:45PM GMT
Release Date Price: €44.25 (+0.53%)
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate

Hi, I'm John Sourbeer. I cover Life Science Tools and Pharma Services at UBS. For our next fireside chat, we have QIAGEN. And with us today is CEO, Thierry Bernard. Hi, Thierry.

Thierry Bernard
Qiagen N.V. - CEO, MD & Member of Management Board

Thank you.

Questions & Answers

John Newton Sourbeer;Thierry Bernard
UBS Investment Bank, Research Division - Equity Research Associate;Qiagen N.V. - CEO, MD & Member of Management Board<

And a reminder: if you like, we have iPads up here. And through the UBS app, you can ask a question if you have any questions in the audience. So Thierry, I figured just to start things off, COVID testing continues to be a topic of interest.

Can you just talk a little bit about the cadence of the COVID testing guidance for the year? I think it's $14 million. And then -- how do you see this normalizing as we see cases drop throughout the year?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot